MIT chemists introduced antibody–bottlebrush prodrugs that enable higher drug loads and payload diversity compared to traditional antibody-drug conjugates (ADCs), showing favorable preclinical efficacy. Meanwhile, new immunotherapy drug STF-1623 with prolonged tumor retention targets innate immune checkpoints in tumors to activate immune response against 'cold' tumors. Together, these innovations present new avenues for effective cancer treatment modalities.